Differences in incidence and co‐occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33
Open Access
- 13 September 2010
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 128 (5) , 1114-1119
Abstract
To understand likelihood of type replacement after vaccination against the high‐risk human papillomavirus (HPV) types, we evaluated competition of the seven most common genital HPV types in a population sample of unvaccinated, fertile‐aged Finnish women. First trimester sera from two consecutive pregnancies were retrieved from 3,183 Finnish women (mean age, 23.1 years) of whom 42.3% had antibodies to at least one HPV type (6/11/16/18/31/33/45) at the baseline. Antibody positivity to more than one HPV types by the second pregnancy was common among the baseline HPV seropositives. However, compared to baseline HPV‐seronegative women, significantly increased incidence rate ratios (IRRs), indicating an increased risk to seroconvert for another HPV type, were consistently noted only for HPV33 among baseline HPV16 or HPV18 antibody (ab)‐positive women: HPV16ab only → 16&33ab IRR 2.9 [95% confidence interval (CI) 1.6–5.4] and HPV18ab only → 18&33ab IRR 2.5 (95% CI 1.1–6.0), irrespectively of the presence of antibodies to other HPV types at baseline: HPV16ab → 16&33ab IRR 3.2 (95% CI 2.0–5.2) and HPV18ab → 18&33ab IRR 3.6 (95% CI 2.1–5.9). Our findings suggest a possible competitive advantage for HPV33 over other genital HPV types in the unvaccinated population. HPV33 should be monitored for type replacement after HPV mass vaccination.Keywords
This publication has 23 references indexed in Scilit:
- Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypesScandinavian Journal of Infectious Diseases, 2010
- Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile‐aged Finnish womenInternational Journal of Cancer, 2009
- Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young ChildrenPediatrics, 2009
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- High-risk and multiple human papillomavirus (HPV) infections in cancer-free Jamaican womenInfectious Agents and Cancer, 2009
- Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, UgandaInternational Journal of Cancer, 2008
- Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays—an updateVaccine, 2006
- Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling AnalysesPLOS Medicine, 2006
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysisBritish Journal of Cancer, 2003
- Concurrent and Sequential Acquisition of Different Genital Human Papillomavirus TypesThe Journal of Infectious Diseases, 2000